HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 182 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,755,932 | -3.6% | 755,445 | +3.5% | 0.00% | 0.0% |
| Q2 2023 | $25,689,545 | +40.0% | 730,024 | +29.9% | 0.00% | +50.0% |
| Q1 2023 | $18,351,650 | -16.0% | 562,072 | +41.8% | 0.00% | 0.0% |
| Q4 2022 | $21,837,012 | +52.7% | 396,316 | +22.8% | 0.00% | 0.0% |
| Q3 2022 | $14,296,000 | +37.3% | 322,782 | +51.2% | 0.00% | +100.0% |
| Q2 2022 | $10,412,000 | +32.5% | 213,477 | +32.1% | 0.00% | 0.0% |
| Q1 2022 | $7,861,000 | +7.7% | 161,574 | -5.6% | 0.00% | 0.0% |
| Q4 2021 | $7,297,000 | +327.7% | 171,107 | +284.6% | 0.00% | – |
| Q3 2021 | $1,706,000 | -53.1% | 44,484 | -65.5% | 0.00% | – |
| Q2 2021 | $3,634,000 | +72.3% | 128,756 | +101.7% | 0.00% | – |
| Q1 2021 | $2,109,000 | +179.3% | 63,827 | +205.9% | 0.00% | – |
| Q4 2020 | $755,000 | +37650.0% | 20,866 | +41632.0% | 0.00% | – |
| Q3 2020 | $2,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |